Literature DB >> 9077725

Esophagectomy in patients with polysplenia: technical considerations.

D D Oakes1.   

Abstract

We report a case and discuss the special considerations necessary for safe treatment of patients with polysplenia who require esophagectomy for cancer or other conditions. Polysplenia is a form of abnormal arrangement of body organs intermediate between situs solitus and situs inversus, sometimes associated with cardiac abnormalities. Abdominal manifestations include multiple spleens, a preduodenal portal vein, an interrupted inferior vena with azygous continuation, a short pancreas, and intestinal malrotation and malformations with anomalous blood supply. Esophagectomy is complicated in such patients by possible cardiac abnormalities, risk of hemorrhage from the enlarged azygous vein (adjacent to distal esophagus), limited exposure via right thoracotomy because of the dilated azygous venous system, and possibly restricted availability of stomach and colon for esophageal replacement (constraints of mobility stemming from anomalous blood supply and malposition/malrotation).

Entities:  

Mesh:

Year:  1997        PMID: 9077725     DOI: 10.1097/00004836-199703000-00010

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  3 in total

Review 1.  Preduodenal portal vein, intestinal malrotation, polysplenia, and interruption of the inferior vena cava: a review of anatomical anomalies associated with gastric cancer.

Authors:  Kenji Mimatsu; Takatsugu Oida; Hisao Kano; Atsushi Kawasaki; Nobutada Fukino; Kazutoshi Kida; Youichi Kuboi; Sadao Amano
Journal:  Surg Radiol Anat       Date:  2011-11-12       Impact factor: 1.246

2.  Pancreatic adenocarcinoma in a patient with situs inversus: a case report of this rare coincidence.

Authors:  Eric L Sceusi; Curtis J Wray
Journal:  World J Surg Oncol       Date:  2009-12-18       Impact factor: 2.754

3.  A patient of situs ambiguus with pancreatic head cancer successfully treated with gemcitabine and erlotinib.

Authors:  Po-Chou Lin; Jiun-I Lai; Cheng-Hwai Tzeng; Wei-Shu Wang
Journal:  Med Oncol       Date:  2010-01-22       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.